Pixium Vision - Remote rehabilitation system approved
Pixium has received regulatory approval in multiple countries (France, Germany, Italy, Spain and the Netherlands) for its remote rehabilitation system, designed for use in patients enrolled in its PRIMAvera pivotal study and the French feasibility study. These trials assess the Prima wireless bionic vision system (BVS) in patients with geographic atrophy due to age-related macular degeneration (GA-AMD), and Pixium continues to expect PRIMAvera primary endpoint data at around year-end 2023. We view this development as positive, as provided the Prima BVS gains regulatory approval, the availability of a remote rehabilitation system helps provide a more accessible training platform (as many GA-AMD patients may have mobility challenges), which could help support product uptake.Pixium Vision SA is a company that specializes in sensorial neuromodulation. Co. is also collaborating with scientific groups and clinicians at research institutes and clinical centers around the world, including Stanford University (USA). Co. is developing and aims to commercialize Bionic Vision Systems (BVS) – namely active implantable medical devices to treat blindness caused by degeneration of photoreceptor cells in the retina.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.